Chintamani* , Chintamani* J.P. Singh** Rohan Khandelwal*** Megha Tandon**** Usha Agarwal***** Sunita Saxena******
Neo-adjuvant chemotherapy (NACT) is an integral part of multi-modality approach in the management of locally advanced breast cancer (LABC). It is required both for the local control (to ensure microscopically free margins during surgery) and distant or systemic control [1-6]. Development of resistance to chemotherapeutic agents is a major and evolving problem. Various markers like P-Glycoprotein, tumor suppressor gene p53, apoptotic markers( Bcl-2, Bax) have been studied to predict the response to NACT[1].
Key words: Hemoglobin, breast cancer, neoadjuvant, Chemotherapy.
No records found.
You may search for similar articles that contain these
Saturday 19 April 2025, 05:10:03 (IST)
View full article metrics including social shares, article views and publishing history
Highlight selected keywords in the article text.
Received | N/A |
Accepted | N/A |
Published | N/A |